<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2457">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04456088</url>
  </required_header>
  <id_info>
    <org_study_id>BAI_COV19_01_CAN</org_study_id>
    <nct_id>NCT04456088</nct_id>
  </id_info>
  <brief_title>Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (CANADA Trial)</brief_title>
  <official_title>Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beyond Air Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beyond Air Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this open label, 2-phase, study is to obtain information on the safety of 80
      ppm and the safety and efficacy of 150 ppm Nitric Oxide given in addition to the standard of
      care of patients with COVID-19 caused by SARS-CoV-2.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 15, 2020</start_date>
  <completion_date type="Anticipated">December 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a two phase study. The first 10 subjects will be treated with 80ppm NO; The remaining 40 subjects will be randomized in 1:1 ratio with subjects receiving 150 NO+SST or the SST alone.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to deterioration</measure>
    <time_frame>up to 14 days</time_frame>
    <description>Time to deterioration as measured by any one of the following:
need for non-invasive ventilation
need for high flow nasal cannula (HFNC) or
need for intubation
Death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to stable oxygen saturation</measure>
    <time_frame>up to 14 days</time_frame>
    <description>Time to patient having stable oxygen saturation (SpO2) of greater than 92% for longer than 3 hr on room air</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Treatment Emergent Adverse Events and SAEs</measure>
    <time_frame>30 days after last inhalation treatment</time_frame>
    <description>Treatment Emergent Adverse Events and SAEs - safety evaluation for 30 days after last inhalation treatment</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>COVID-19</condition>
  <condition>SARS-CoV 2</condition>
  <condition>Respiratory Disease</condition>
  <condition>Pneumonia, Viral</condition>
  <condition>Corona Virus Infection</condition>
  <arm_group>
    <arm_group_label>Phase 1- Nitric oxide treatment- 80ppm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2- Group 1- Nitric oxide treatment- 150ppm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2- Group 2- control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of Care</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>150 ppm Nitric Oxide delivered through LungFit Delivery System</intervention_name>
    <description>Nitric Oxide delivered via LungFit system. Patients will receive inhalations of 150 ppm for 40 minutes 4 time per day plus standard supportive care.</description>
    <arm_group_label>Phase 2- Group 1- Nitric oxide treatment- 150ppm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>80 ppm Nitric Oxide delivered through LungFit Delivery System</intervention_name>
    <description>Nitric Oxide delivered via LungFit system. Patients will receive inhalations of 80 ppm for 40 minutes 4 time per day plus standard supportive care.</description>
    <arm_group_label>Phase 1- Nitric oxide treatment- 80ppm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients (male and female) admitted to the hospital for COVID-19

          2. Patients with oxygen saturation less than 93 % on room air

          3. Shortness of breath, with symptom onset within the previous 8 days.

          4. Ability to understand and comply with study requirements .

          5. Signed informed consent by subject

        Exclusion Criteria:

          1. Patients who are treated with or require high flow nasal cannula, CPAP, intubation,
             mechanical ventilation, or tracheostomy

          2. Diagnosis of acute respiratory distress syndrome

          3. Breastfeeding or pregnancy as evidenced by a positive pregnancy test.

          4. Subjects diagnosed with immunodeficiency, with history of congestive or unstable heart
             disease, left ventricular dysfunction (LVEF &lt;40%) or myocardial damage, severe
             pulmonary hypertension and/or unstable hypertension

          5. History of frequent epistaxis (&gt;1 episode/month).

          6. Significant hemoptysis during the last 30 days prior to enrollment

          7. Methemoglobin level &gt;3% at screening

          8. Patients on systemic steroids (any formulation) within 30 days prior to enrollment.

          9. History of daily, continuous oxygen supplementation

         10. Patients with BMI greater than or equal to 36

         11. Patient receiving drugs that have a contraindication with NO,

         12. Patients with clinically significant anemia, e.g., Hb &lt;100 g/L and thrombocytopenia,
             e.g., Platelets &lt;75 thousand cells/mcL.

         13. Presence of a condition or abnormality that in the opinion of the Investigator would
             compromise the safety of the subject or the quality of the data, e.g., known or
             suspected thalassemia, sickle cell disease or other diseases associated with poor
             oxygen carrying capacity.

         14. The subject is identified by the investigator as being unable or unwilling to perform
             study procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Asher Tal, MD</last_name>
    <role>Study Director</role>
    <affiliation>Beyond Air</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rinat Kalaora</last_name>
    <phone>+972-54-4750887</phone>
    <email>rkalaora@beyondair.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Meital Hatan</last_name>
    <phone>+972-52-3215515</phone>
    <email>mhatan@beyondair.net</email>
  </overall_contact_backup>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 1, 2020</study_first_submitted>
  <study_first_submitted_qc>July 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2020</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Pneumonia, Viral</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

